2022年6月3日～6月7日に米国シカゴとオンラインのハイブリッドで開催された、米国臨床腫瘍学会年次集会（2022 Annual Meeting of the American Society of Clinical Oncology®）より、大腸癌や胃癌などの消化器癌の注目演題のレポートをお届けします。臨床研究の第一線で活躍するドクターにより執筆、監修されたレポートを楽しみにしてください。
Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO
Chiara Cremolini, et al.
Panitumumab plus mFOLFOX6 versus Bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type metastatic colorectal cancer: results from the phase 3 PARADIGM trial
Takayuki Yoshino, et al.
FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases （CRLM） and right-sided and/or RAS/BRAFV600E mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group
Cornelis J. A. Punt, et al.
Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial
Jeanne Tie, et al.
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial)
Akihiro Ohba, et al.